Attomarker Ltd

Attomarker is a British company focused on nanophotonic biochemical testing. It was founded in 2008, and spun out from Professor Andrew Shaw’s research group at the University of Exeter. It has won numerous prestigious awards for innovation and been awarded grants for research from the UK Government due to the importance of its work. Attomarker works in the personalised medicine market and is committed to providing gold-standard rapid diagnostics to enable better and more timely decisions about health and health interventions. It has a significant pipeline of tests but is currently focused on four of the most important global health challenges: COVID-19, Obesity, Food Allergy and Antimicrobial Resistance (AMR).